Can-Fite BioPharma Files 6-K, Incorporates Inducement Letter
Ticker: CANF · Form: 6-K · Filed: Aug 12, 2024 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | Aug 12, 2024 |
| Risk Level | medium |
| Pages | 8 |
| Reading Time | 9 min |
| Key Dollar Amounts | $1.75, $2.25, $5.0 million, $2.1875, $50,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, registration-statement, investor-relations
TL;DR
Can-Fite BioPharma filed a 6-K on Aug 8, 2024, referencing an investor inducement letter, potentially affecting financing.
AI Summary
On August 8, 2024, Can-Fite BioPharma Ltd. entered into an inducement letter with an investor. This letter is incorporated by reference into several of the Company's existing registration statements on Form S-8 and Form F-3. The filing does not provide specific details on the investor or the terms of the inducement.
Why It Matters
This filing indicates a potential new agreement or incentive involving an investor, which could impact the company's capital structure or future financing activities.
Risk Assessment
Risk Level: medium — The filing references an 'inducement letter' without detailing its terms, creating uncertainty about potential financial implications or investor relations.
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — Registrant
- August 8, 2024 (date) — Date of inducement letter
- Form S-8 (document) — Incorporated registration statement
- Form F-3 (document) — Incorporated registration statement
FAQ
What is the nature of the inducement letter Can-Fite BioPharma entered into on August 8, 2024?
The filing does not specify the nature or terms of the inducement letter, only that it was entered into with an investor.
Which registration statements does this Form 6-K filing incorporate by reference?
This Form 6-K is incorporated by reference into Can-Fite BioPharma's Registration Statements on Form S-8 (File Nos. 333-227753, 333-271384, and 333-278525) and Form F-3 (File Nos. 333-195124, 333-236064, 333-249063, 333-262055, and 333-276000).
What is the principal executive office address for Can-Fite BioPharma Ltd.?
The principal executive offices are located at 26 Ben Gurion Street, Ramat Gan 5257346, Israel.
What is the SIC code for Can-Fite BioPharma Ltd.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
When is Can-Fite BioPharma Ltd.'s fiscal year end?
The company's fiscal year ends on December 31st (1231).
Filing Stats: 2,308 words · 9 min read · ~8 pages · Grade level 15.8 · Accepted 2024-08-12 06:45:11
Key Financial Figures
- $1.75 — anuary 13, 2023 at an exercise price of $1.75 per ADS (the “January 2023 Series
- $2.25 — Shares”), at an exercise price of $2.25 per ADS. The Company expects to receive
- $5.0 million — gregate gross proceeds of approximately $5.0 million from the exercise of the Existing Warra
- $2.1875 — ts will have an exercise price equal to $2.1875 per share (125% of the reduced exercise
- $50,000 — agreed to pay the Placement Agent up to $50,000 for non-accountable expenses, $25,000 f
- $25,000 — o $50,000 for non-accountable expenses, $25,000 for accountable expenses and $15,950 fo
- $15,950 — s, $25,000 for accountable expenses and $15,950 for clearing fees. The closing of the
Filing Documents
- ea021093201-6k_canfite.htm (6-K) — 32KB
- ea021093201ex10-1_canfite.htm (EX-10.1) — 47KB
- ea021093201ex10-2_canfite.htm (EX-10.2) — 113KB
- ea021093201ex10-3_canfite.htm (EX-10.3) — 114KB
- 0001213900-24-067357.txt ( ) — 307KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: August 12, 2024 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer 4